Safety, pharmacokinetic, and pharmacodynamic evaluation of a 2-(2-methoxyethyl)-d-ribose antisense oligonucleotide-triantenarry n -acetyl-galactosamine conjugate that targets the human transmembrane protease serine 6
The truth is simple: when you stop treating a chronic disease, it comes back
The secondary sources used for this study include the World Health Organization (WHO), the National Institutes of Health (NIH), the International Society for Pharmaceutical Engineering (ISPE), BioPharm International, the US Food and Drug Administration (US FDA), the European Medicines Agency (EMA), the Parenteral Drug Association (PDA), the Pharma & Biopharma Outsourcing Association (PBOA), the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the National Center for Biotechnology Information (NCBI), the International Trade Centre (ITC), Press Releases, company websites, and magazines & proprietary databases
Delivery method is another major factor
Journal of Functional Morphology and Kinesiology
CDC and FDA guidance say otherwise